Modality
mRNA
MOA
SOS1i
Target
MET
Pathway
Lipid Met
LNEwing Sarcoma
Development Pipeline
Preclinical
~Apr 2010
→ ~Jul 2011
Phase 1
~Oct 2011
→ ~Jan 2013
Phase 2
~Apr 2013
→ ~Jul 2014
Phase 3
~Oct 2014
→ ~Jan 2016
NDA/BLA
~Apr 2016
→ ~Jul 2017
Approved
Oct 2017
→ Jun 2026
ApprovedCurrent
NCT04186396
2,352 pts·LN
2017-10→2026-06·Active
2,352 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2026-06-152mo awayPh3 Readout· LN
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Approved
Active
Catalysts
Ph3 Readout
2026-06-15 · 2mo away
LN
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04186396 | Approved | LN | Active | 2352 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |